Last reviewed · How we verify
CBD+THC
At a glance
| Generic name | CBD+THC |
|---|---|
| Sponsor | Hamilton Health Sciences Corporation |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Analysis of the Therapeutic and Clinical Profile of Cannabinoid Treatments: A Real-World Study
- PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product (PHASE2)
- Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder (PHASE2)
- Investigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults (PHASE2)
- Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia (EARLY_PHASE1)
- EFFECTS OF A FULL SPECTRUM CANNABIS EXTRACT WITH DIFFERENT DOSES OF CBD AND THC ON THE MODULATION OF FIBROMYALGIA: A PILOT, MULTICENTER, OPEN LABEL CLINICAL TRIAL (FRIDINHA) (PHASE1,PHASE2)
- Evaluation of Smoked THC and CBD in Men and Women (PHASE1)
- Dose-Ranging Trial of Inhaled Cannabis for Acute Migraine Treatment (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CBD+THC CI brief — competitive landscape report
- CBD+THC updates RSS · CI watch RSS
- Hamilton Health Sciences Corporation portfolio CI